Along with the appropriate Philips patient monitoring platform, Masimo rainbow SET technology can study multiple wavelengths of light to accurately measure total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet) and Pleth Variability Index (PVI) noninvasively and continuously.

According to Philips, the continuous monitoring of rainbow SpHb on its monitor at the point-of-care offers clinicians with real-time visibility to changes in hemoglobin in between invasive blood sampling.

The company is also providing option to its customers to add rainbow SET to existing IntelliVue monitors.

Plans are underway to incorporate the technology into Philips SureSigns and Efficia patient monitoring platforms.

Depending on the patient requirements, the company is offering Philips FAST SpO2 pulse oximetry and Covidien’s OxiMax SpO2 pulse oximetry.

In February, Philips announced the launch of a new wearable biosensor enabled monitoring solution for at-risk patients in low acuity hospital settings like the general ward.

The connected biosensor is said to automatically and continuously measure the appropriate clinical indications such as heart rate, respiratory rate, skin temperature and others.

Philips provides a range of patient monitoring solutions ranging from bedside monitors to wearable patient monitors.

With operations in around 100 countries, the company offers diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as consumer health and home care services.